Tarsus Pharmaceuticals Inc
TARS81.870USD
-0.640-0.78%
Market hours （ET）Quotes delayed by 15 min
3.48BMarket Cap
LossP/E TTM
More Details of Tarsus Pharmaceuticals Inc Company
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals Inc Info
Ticker SymbolTARS
Company nameTarsus Pharmaceuticals Inc
IPO dateOct 16, 2020
CEOAzamian (Bobak)
Number of employees323
Security typeOrdinary Share
Fiscal year-endOct 16
Address15440 Laguna Canyon Road
CityIRVINE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92618
Phone19494099820
Websitehttps://www.tarsusrx.com/
Ticker SymbolTARS
IPO dateOct 16, 2020
CEOAzamian (Bobak)
Company Executives of Tarsus Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. William J. Link, Ph.D.
Dr. William J. Link, Ph.D.
Independent Director
Independent Director
151.78K
-16.10%
Dr. Seshadri Neervannan, Ph.D.
Dr. Seshadri Neervannan, Ph.D.
Chief Operating Officer
Chief Operating Officer
79.68K
+23.03%
Dr. Bryan Wahl, M.D., J.D.
Dr. Bryan Wahl, M.D., J.D.
General Counsel, Secretary
General Counsel, Secretary
49.09K
+24.08%
Mr. Aziz Mottiwala
Mr. Aziz Mottiwala
Chief Commercial Officer
Chief Commercial Officer
47.56K
-26.90%
Ms. Dianne C. Whitfield
Ms. Dianne C. Whitfield
Chief Human Resources Officer
Chief Human Resources Officer
44.38K
+37.80%
Mr. Jeffrey S. (Jeff) Farrow
Mr. Jeffrey S. (Jeff) Farrow
Chief Financial Officer and Chief Strategy Officer
Chief Financial Officer and Chief Strategy Officer
36.70K
+63.63%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Lead Independent Director
Lead Independent Director
13.70K
+32.37%
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
8.70K
+62.62%
Dr. Andrew Goldberg, M.D.
Dr. Andrew Goldberg, M.D.
Independent Director
Independent Director
--
--
Dr. Elizabeth Yeu, M.D.
Dr. Elizabeth Yeu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. William J. Link, Ph.D.
Dr. William J. Link, Ph.D.
Independent Director
Independent Director
151.78K
-16.10%
Dr. Seshadri Neervannan, Ph.D.
Dr. Seshadri Neervannan, Ph.D.
Chief Operating Officer
Chief Operating Officer
79.68K
+23.03%
Dr. Bryan Wahl, M.D., J.D.
Dr. Bryan Wahl, M.D., J.D.
General Counsel, Secretary
General Counsel, Secretary
49.09K
+24.08%
Mr. Aziz Mottiwala
Mr. Aziz Mottiwala
Chief Commercial Officer
Chief Commercial Officer
47.56K
-26.90%
Ms. Dianne C. Whitfield
Ms. Dianne C. Whitfield
Chief Human Resources Officer
Chief Human Resources Officer
44.38K
+37.80%
Mr. Jeffrey S. (Jeff) Farrow
Mr. Jeffrey S. (Jeff) Farrow
Chief Financial Officer and Chief Strategy Officer
Chief Financial Officer and Chief Strategy Officer
36.70K
+63.63%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
7.49%
BlackRock Institutional Trust Company, N.A.
7.27%
Deep Track Capital LP
7.07%
Paradigm BioCapital Advisors LP
6.28%
Jennison Associates LLC
6.14%
Other
65.76%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
7.49%
BlackRock Institutional Trust Company, N.A.
7.27%
Deep Track Capital LP
7.07%
Paradigm BioCapital Advisors LP
6.28%
Jennison Associates LLC
6.14%
Other
65.76%
Shareholder Types
Shareholders
Proportion
Investment Advisor
35.85%
Investment Advisor/Hedge Fund
34.80%
Hedge Fund
26.32%
Research Firm
8.74%
Private Equity
3.23%
Individual Investor
3.10%
Sovereign Wealth Fund
1.11%
Pension Fund
0.91%
Bank and Trust
0.26%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
423
49.17M
115.83%
-3.53M
2025Q2
402
46.20M
109.45%
-3.88M
2025Q1
407
48.50M
115.53%
-3.34M
2024Q4
378
44.81M
116.78%
-6.00M
2024Q3
339
47.74M
124.97%
+1.40M
2024Q2
315
44.21M
116.20%
+181.38K
2024Q1
291
44.53M
119.96%
+4.60M
2023Q4
241
35.50M
106.12%
-146.85K
2023Q3
226
34.34M
108.40%
+5.84M
2023Q2
202
25.92M
97.99%
-1.52M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
3.11M
7.37%
-204.35K
-6.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.11M
7.37%
+281.38K
+9.94%
Jun 30, 2025
Deep Track Capital LP
2.35M
5.57%
+602.96K
+34.45%
Jul 21, 2025
Paradigm BioCapital Advisors LP
2.98M
7.05%
+365.90K
+14.02%
Jun 30, 2025
Jennison Associates LLC
2.47M
5.85%
-24.64K
-0.99%
Jun 30, 2025
Tang Capital Management, LLC
2.45M
5.82%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.29M
5.42%
+69.64K
+3.14%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.82M
4.32%
+79.49K
+4.56%
Jun 30, 2025
Janus Henderson Investors
1.81M
4.28%
+1.29M
+252.26%
Jun 30, 2025
Assenagon Asset Management S.A.
1.25M
2.96%
+250.37K
+25.10%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
3.3%
State Street SPDR S&P Pharmaceuticals ETF
3.3%
Invesco Pharmaceuticals ETF
3.12%
Virtus LifeSci Biotech Products ETF
2.69%
Innovator IBD 50 Fund ETF
2.11%
ALPS Medical Breakthroughs ETF
1.28%
iShares U.S. Pharmaceuticals ETF
0.99%
First Trust Small Cap Growth AlphaDEX Fund
0.78%
Harbor Human Capital Factor US Small Cap ETF
0.76%
First Trust Multi-Manager Small Cap Opportunities ETF
0.66%
View more
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion3.3%
State Street SPDR S&P Pharmaceuticals ETF
Proportion3.3%
Invesco Pharmaceuticals ETF
Proportion3.12%
Virtus LifeSci Biotech Products ETF
Proportion2.69%
Innovator IBD 50 Fund ETF
Proportion2.11%
ALPS Medical Breakthroughs ETF
Proportion1.28%
iShares U.S. Pharmaceuticals ETF
Proportion0.99%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.78%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.76%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.66%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Tarsus Pharmaceuticals Inc?
The top five shareholders of Tarsus Pharmaceuticals Inc are:
RTW Investments L.P. holds 3.11M shares, accounting for 7.37% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.11M shares, accounting for 7.37% of the total shares.
Deep Track Capital LP holds 2.35M shares, accounting for 5.57% of the total shares.
Paradigm BioCapital Advisors LP holds 2.98M shares, accounting for 7.05% of the total shares.
Jennison Associates LLC holds 2.47M shares, accounting for 5.85% of the total shares.
RTW Investments L.P. holds 3.11M shares, accounting for 7.37% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.11M shares, accounting for 7.37% of the total shares.
Deep Track Capital LP holds 2.35M shares, accounting for 5.57% of the total shares.
Paradigm BioCapital Advisors LP holds 2.98M shares, accounting for 7.05% of the total shares.
Jennison Associates LLC holds 2.47M shares, accounting for 5.85% of the total shares.
What are the top three shareholder types of Tarsus Pharmaceuticals Inc?
The top three shareholder types of Tarsus Pharmaceuticals Inc are:
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
Deep Track Capital LP
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
Deep Track Capital LP
How many institutions hold shares of Tarsus Pharmaceuticals Inc (TARS)?
As of 2025Q3, 423 institutions hold shares of Tarsus Pharmaceuticals Inc, with a combined market value of approximately 49.17M, accounting for 115.83% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 6.38%.
What is the biggest source of revenue for Tarsus Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Tarsus Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
